查看所有供应商和价格请点击:
1246816-81-8生产厂家
1246816-81-8价格
化源商城直购
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K.Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.J Pharm Biomed Anal. 2011 Sep 10;56(2):429-35.
[3]. Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H.Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2010 Aug;136(2):113-20.
[4]. Ruhlmann C, Herrstedt J.Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48.
[5]. Trissel LA, Trusley C, Ben M, Kupiec TC.Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13.
[6]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.J. Med. Chem., 1993, 36 (18), pp 2645-2657